Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC

van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–55.

Tower J. Developmental gene amplification and origin regulation. Annu Rev Genet. 2004;38:273–304.

Hnisz D, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934–47.

Pott S, Lieb JD. What are super-enhancers? Nat Genet. 2015;47(1):8–12.

Herranz D, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med. 2014;20(10):1130–7.

Sabari BR, et al. Coactivator condensation at super-enhancers links phase separation and gene control. Science (New York, NY). 2018;361(6400):eaar3958.

Lovén J, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320–34.

Shin HY. Targeting Super-Enhancers for Disease Treatment and Diagnosis. Mol Cell. 2018;41(6):506–14.

Stower H. Gene expression: Super enhancers. Nat Rev Genet. 2013;14(6):367.

Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137.

Brozzi A, et al. CARPET: a web-based package for the analysis of ChIP-chip and expression tiling data. Bioinformatics. 2008;24(24):2918–20.

Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of Cancer. Cancer Cell. 2018;34(1):21–43.

Tripathi SC, et al. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. Cancer Res. 2017;77(16):4414–25.

Robey RW, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452–64.

Sengupta S, George RE. Super-Enhancer-Driven Transcriptional Dependencies in Cancer. Trends Cancer. 2017;3(4):269–81.

Huang J, et al. Dissecting super-enhancer hierarchy based on chromatin interactions. Nat Commun. 2018;9(1):943.

Hay D, et al. Genetic dissection of the alpha-globin super-enhancer in vivo. Nat Genet. 2016;48(8):895–903.

Gupta S, et al. Quantifying similarity between motifs. Genome Biol. 2007;8(2):R24.

Ganesan S. MYC, PARP1, and chemoresistance: BIN there, done that? Sci Signal. 2011;4(166):pe15.

Corvaisier M, et al. Regulation of cellular quiescence by YAP/TAZ and cyclin E1 in colon cancer cells: implication in chemoresistance and cancer relapse. Oncotarget. 2016;7(35):56699–712.

Huang TS, et al. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol Cancer. 2007;6:31.

Kuhnl A, et al. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res. 2011;35(12):1585–90.

Whyte WA, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307–19.

Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013;152(6):1237–51.

Levine M, Cattoglio C, Tjian R. Looping back to leap forward: transcription enters a new era. Cell. 2014;157(1):13–25.

Levine M. Transcriptional enhancers in animal development and evolution. Curr Biol. 2010;20(17):R754–63.

Bradner JE, Hnisz D, Young RA. Transcriptional addiction in Cancer. Cell. 2017;168(4):629–43.

Adesso L, et al. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene. 2013;32(23):2848–57.

Hu J, et al. The plasma microRNA miR-1914* and −1915 suppresses Chemoresistant in colorectal Cancer patients by Down-regulating NFIX. Curr Mol Med. 2016;16(1):70–82.